Soligenix (SNGX) Stock Price, News & Analysis

Company Overview

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Key Stats

• Today's Range: $2.92 to $3.00
• 50-Day Range: $2.95 to $3.96
• 52-Week Range: $1.83 to $19.20
• Volume: 47,439 shs
• Average Volume: 762,856 shs
• Market Capitalization: $7.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Soligenix Stock Analysis - MarketRank™

Soligenix scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Soligenix.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Soligenix are expected to grow in the coming year, from ($4.65) to ($2.93) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Soligenix is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Soligenix is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Soligenix has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.46% of the float of Soligenix has been sold short.

Short Interest Ratio / Days to Cover

Soligenix has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Soligenix has recently decreased by 20.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Soligenix does not currently pay a dividend.

Dividend Growth

Soligenix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.46% of the float of Soligenix has been sold short.

Short Interest Ratio / Days to Cover

Soligenix has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Soligenix has recently decreased by 20.22%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 5 news articles for Soligenix this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Soligenix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Soligenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.80% of the stock of Soligenix is held by insiders.

Percentage Held by Institutions

Only 3.60% of the stock of Soligenix is held by institutions.

SNGX Stock Analysis - Frequently Asked Questions

How have SNGX shares performed this year?

Soligenix's stock was trading at $12.1152 on January 1st, 2024. Since then, SNGX stock has decreased by 75.7% and is now trading at $2.95.
View the best growth stocks for 2024 here.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) announced its quarterly earnings results on Friday, November, 12th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, topping analysts' consensus estimates of ($1.92) by $0.48. The biopharmaceutical company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.80 million. Soligenix had a negative net margin of 1,473.38% and a negative trailing twelve-month return on equity of 223.29%.

When did Soligenix's stock split?

Soligenix shares reverse split on the morning of Thursday, June 6th 2024. The 1-16 reverse split was announced on Thursday, June 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Who are Soligenix's major shareholders?

Soligenix's top institutional shareholders include Stephens Inc. AR (4.69%). Insiders that own company stock include Christopher J Schaber and Richard Straube.
View institutional ownership trends.

How do I buy shares of Soligenix?

Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Soligenix investors own include Tonix Pharmaceuticals (TNXP), Trevena (TRVN), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), T2 Biosystems (TTOO), iBio (IBIO) and Dynavax Technologies (DVAX).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNGX
• CUSIP: N/A
• CIK: 812796
• Web: www.soligenix.com
• Phone: (609) 538-8200
• Fax: 609-452-6467
• Employees: 20
• Year Founded: 1987

Profitability

• EPS (Most Recent Fiscal Year): ($7.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,140,000.00
• Net Margins: -1,473.38%
• Pretax Margin: -2,220.75%
• Return on Equity: -223.29%
• Return on Assets: -74.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.28
• Quick Ratio: 2.28

Sales & Book Value

• Annual Sales: $840,000.00
• Price / Sales: 8.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.83 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 2,510,000
• Free Float: 2,440,000
• Market Cap: $7.40 million
• Optionable: Not Optionable
• Beta: 1.79